Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 525

1.

Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma.

Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H.

J Gastrointest Oncol. 2018 Apr;9(2):275-281. doi: 10.21037/jgo.2018.01.14.

2.

TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Feng H, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Lemoine NR, Heeschen C, Castellano L.

Nat Commun. 2018 May 10;9(1):1845. doi: 10.1038/s41467-018-03962-x.

3.

Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.

Centelles MN, Wright M, So PW, Amrahli M, Xu XY, Stebbing J, Miller AD, Gedroyc W, Thanou M.

J Control Release. 2018 Jun 28;280:87-98. doi: 10.1016/j.jconrel.2018.04.047. Epub 2018 May 1.

PMID:
29723616
4.

Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.

Frampton AE, Prado MM, López-Jiménez E, Fajardo-Puerta AB, Jawad ZAR, Lawton P, Giovannetti E, Habib NA, Castellano L, Stebbing J, Krell J, Jiao LR.

Oncotarget. 2018 Apr 10;9(27):19006-19013. doi: 10.18632/oncotarget.24873. eCollection 2018 Apr 10.

5.

Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Moderau N, Poyia F, Schwartzberg LS, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Feb 24;9(25):17589-17596. doi: 10.18632/oncotarget.24564. eCollection 2018 Apr 3.

6.

Novel tumour suppressive protein encoded by circular RNA, circ-SHPRH, in glioblastomas.

Begum S, Yiu A, Stebbing J, Castellano L.

Oncogene. 2018 Apr 30. doi: 10.1038/s41388-018-0230-3. [Epub ahead of print]

PMID:
29706655
7.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
8.

Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Herzog T, Levitan J, Moderau N, Schwartzberg L, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Mar 13;9(19):15166. doi: 10.18632/oncotarget.24691. eCollection 2018 Mar 13.

9.

Correction: The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.

Carter P, Alifrangis C, Chandrasinghe P, Cereser B, Del Bel Belluz L, Leo CA, Moderau N, Tabassum N, Warusavitarne J, Krell J, Stebbing J.

Oncotarget. 2018 Mar 13;9(19):15165. doi: 10.18632/oncotarget.24690. eCollection 2018 Mar 13.

10.

Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J.

Oncotarget. 2018 Mar 13;9(19):15164. doi: 10.18632/oncotarget.24689. eCollection 2018 Mar 13.

11.

Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.

Stebbing J, Baranau Y, Manikhas A, Lee SJ, Thiruchelvam P, Leff D, Esteva FJ.

Expert Rev Anticancer Ther. 2018 Jun;18(6):531-541. doi: 10.1080/14737140.2018.1457442. Epub 2018 Apr 2.

PMID:
29580109
12.

Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis.

Tzoulis P, Corbett RW, Ponnampalam S, Baker E, Heaton D, Doulgeraki T, Stebbing J.

Endocrinol Diabetes Metab Case Rep. 2018 Mar 21;2018. pii: 18-0111. doi: 10.1530/EDM-18-0111. eCollection 2018.

13.

Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.

Pannuti A, Filipovic A, Hicks C, Lefkowitz E, Ptacek T, Stebbing J, Miele L.

PLoS One. 2018 Mar 23;13(3):e0194790. doi: 10.1371/journal.pone.0194790. eCollection 2018.

14.

Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments.

Alifrangis C, Carter P, Cereser B, Chandrasinghe P, Belluz LDB, Lim E, Moderau N, Poyia F, Tabassum N, Zhang H, Krell J, Stebbing J.

Oncotarget. 2018 Feb 1;9(16):12805-12811. doi: 10.18632/oncotarget.24375. eCollection 2018 Feb 27.

15.

The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.

Carter P, Alifrangis C, Chandrasinghe P, Cereser B, Del Bel Belluz L, Leo CA, Moderau N, Tabassum N, Warusavitarne J, Krell J, Stebbing J.

Oncotarget. 2018 Jan 16;9(13):11371-11376. doi: 10.18632/oncotarget.24257. eCollection 2018 Feb 16. Erratum in: Oncotarget. 2018 Mar 13;9(19):15165.

16.

LMTK3 confers chemo-resistance in breast cancer.

Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, Wendler F, Simon T, Szabó KS, O'Hanlon T, Dean M, Roslani AC, Cheah SH, Lee SC, Giamas G.

Oncogene. 2018 Jun;37(23):3113-3130. doi: 10.1038/s41388-018-0197-0. Epub 2018 Mar 15.

17.

Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Belluz LDB, Herzog T, Levitan J, Moderau N, Schwartzberg L, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Jan 16;9(10):9456-9467. doi: 10.18632/oncotarget.24258. eCollection 2018 Feb 6. Erratum in: Oncotarget. 2018 Mar 13;9(19):15166.

18.

Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.

Esteva FJ, Saeki T, Kim H, Stebbing J.

Future Oncol. 2018 Feb 27. doi: 10.2217/fon-2017-0679. [Epub ahead of print]

PMID:
29482364
19.

Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J.

Oncotarget. 2017 Dec 27;9(5):6007-6014. doi: 10.18632/oncotarget.23675. eCollection 2018 Jan 19. Erratum in: Oncotarget. 2018 Mar 13;9(19):15164.

20.

Targeted cancer therapies: Oral health care implications.

Georgakopoulou E, Stebbing J, Scully C.

J Am Dent Assoc. 2018 Feb;149(2):100-111. doi: 10.1016/j.adaj.2017.08.046.

PMID:
29389333
21.

Harms of cigarette smoking: call to increase knowledge among children.

Lonergan B, Harding V, Cohen H, Wylleman E, Cohen R, Stebbing J.

Eur J Cancer Prev. 2018 Jan 30. doi: 10.1097/CEJ.0000000000000409. [Epub ahead of print]

PMID:
29384759
22.

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.

Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):505-514. doi: 10.1007/s00280-017-3510-7. Epub 2018 Jan 12.

23.

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation.

Soraas L, Stebbing J.

J Thorac Oncol. 2018 Mar;13(3):454-458. doi: 10.1016/j.jtho.2017.11.128. Epub 2017 Dec 13.

PMID:
29246834
24.

Thirty years of Oncogene.

Miller G, Stebbing J.

Oncogene. 2018 Feb 1;37(5):553-554. doi: 10.1038/onc.2017.388. Epub 2017 Oct 23. No abstract available.

25.

The importance of being earnest in post-publication review: scientific fraud and the scourges of anonymity and excuses.

Stebbing J, Sanders DA.

Oncogene. 2018 Feb 8;37(6):695-696. doi: 10.1038/onc.2017.390. Epub 2017 Oct 16. No abstract available.

26.

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D.

Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.

PMID:
28945830
27.

Liquorice: a treatment for all sorts?

Harding V, Stebbing J.

Lancet Oncol. 2017 Sep;18(9):1155. doi: 10.1016/S1470-2045(17)30628-9. No abstract available.

28.

Role of SMAD proteins in colitis-associated cancer: from known to the unknown.

Chandrasinghe P, Cereser B, Moorghen M, Al Bakir I, Tabassum N, Hart A, Stebbing J, Warusavitarne J.

Oncogene. 2018 Jan 4;37(1):1-7. doi: 10.1038/onc.2017.300. Epub 2017 Sep 4. Review.

29.

The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.

Zanini E, Louis LS, Antony J, Karali E, Okon IS, McKie AB, Vaughan S, El-Bahrawy M, Stebbing J, Recchi C, Gabra H.

Mol Cancer Ther. 2017 Oct;16(10):2246-2256. doi: 10.1158/1535-7163.MCT-17-0081. Epub 2017 Aug 3.

PMID:
28775148
30.

Chilli-too hot to handle?

Craddock C, Cathcart P, Stebbing J.

Lancet Oncol. 2017 Aug;18(8):1005. doi: 10.1016/S1470-2045(17)30522-3. Epub 2017 Jul 26. No abstract available.

31.

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017.

32.

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ.

Lancet Oncol. 2017 Jul;18(7):917-928. doi: 10.1016/S1470-2045(17)30434-5. Epub 2017 Jun 4.

33.

Fasting: starving cancer.

Cathcart P, Craddock C, Stebbing J.

Lancet Oncol. 2017 Apr;18(4):431. doi: 10.1016/S1470-2045(17)30196-1. No abstract available.

34.

Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.

Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N.

Cell Rep. 2017 Feb 14;18(7):1687-1698. doi: 10.1016/j.celrep.2017.01.057.

35.

The relationship between ethnicity, social deprivation and late presentation of colorectal cancer.

Askari A, Nachiappan S, Currie A, Latchford A, Stebbing J, Bottle A, Athanasiou T, Faiz O.

Cancer Epidemiol. 2017 Apr;47:88-93. doi: 10.1016/j.canep.2017.01.007. Epub 2017 Feb 4.

PMID:
28167416
36.

Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.

Castellano L, Dabrowska A, Pellegrino L, Ottaviani S, Cathcart P, Frampton AE, Krell J, Stebbing J.

Nucleic Acids Res. 2017 May 5;45(8):4401-4412. doi: 10.1093/nar/gkx022.

37.

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.

Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, Goddard K, Shahin V, Woodley-Barker L, Rosales BM, Coombes RC, Stebbing J, Shaw JA.

Clin Chem. 2017 Feb;63(2):532-541. doi: 10.1373/clinchem.2016.261834. Epub 2016 Dec 9.

38.

Turmeric: a spice for life?

Balachandran K, Stebbing J.

Lancet Oncol. 2016 Dec;17(12):1639. doi: 10.1016/S1470-2045(16)30587-3. No abstract available.

PMID:
27924745
39.

The need for multidisciplinarity in specialist training to optimize future patient care.

Tree AC, Harding V, Bhangu A, Krishnasamy V, Morton D, Stebbing J, Wood BJ, Sharma RA.

Nat Rev Clin Oncol. 2017 Aug;14(8):508-517. doi: 10.1038/nrclinonc.2016.185. Epub 2016 Nov 29. Review.

PMID:
27898067
40.

Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.

Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, Goddard KS, Hastings RK, Luo J, Ogle O, Woodley L, Ali S, Stebbing J, Coombes RC.

Clin Cancer Res. 2017 Jan 1;23(1):88-96. doi: 10.1158/1078-0432.CCR-16-0825. Epub 2016 Jun 22.

41.

Initiation of adjuvant chemotherapy within 8 weeks of elective colorectal resection improves overall survival regardless of reoperation.

Nachiappan S, Askari A, Mamidanna R, Munasinghe A, Currie A, Stebbing J, Faiz O.

Colorectal Dis. 2016 Nov;18(11):1041-1049. doi: 10.1111/codi.13308.

PMID:
27807941
42.

Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer.

Mato Prado M, Frampton AE, Giovannetti E, Stebbing J, Castellano L, Krell J.

Expert Rev Mol Diagn. 2016 Nov;16(11):1155-1162. Epub 2016 Oct 27. Review.

PMID:
27784183
43.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11. No abstract available.

44.

Strategies in functional proteomics: Unveiling the pathways to precision oncology.

Favicchio R, Thepaut C, Zhang H, Arends R, Stebbing J, Giamas G.

Cancer Lett. 2016 Nov 1;382(1):86-94. doi: 10.1016/j.canlet.2016.01.049. Epub 2016 Feb 2. Review.

PMID:
26850375
45.

Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.

Pinato DJ, Shiner RJ, White SD, Black JR, Trivedi P, Stebbing J, Sharma R, Mauri FA.

Oncoimmunology. 2016 Jul 22;5(9):e1213934. eCollection 2016.

46.

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, Metodieva G, de Giorgio A, Williams RL, Santos DB, Gomez PJ, Lin ML, Metodiev MV, Stebbing J, Castellano L, Magnani L, Coombes RC, Buluwela L, Ali S.

Oncogene. 2017 Apr 20;36(16):2286-2296. doi: 10.1038/onc.2016.382. Epub 2016 Oct 17.

47.

The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.

Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI.

J Hepatol. 2017 Feb;66(2):338-346. doi: 10.1016/j.jhep.2016.09.008. Epub 2016 Sep 24.

48.

The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer.

Chandrasinghe P, Stebbing J, Warusavitarne J.

Oncogene. 2017 Mar;36(11):1474-1475. doi: 10.1038/onc.2016.322. Epub 2016 Sep 26.

PMID:
27669439
49.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e16.

50.

Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention.

Wendler F, Favicchio R, Simon T, Alifrangis C, Stebbing J, Giamas G.

Oncogene. 2017 Feb 16;36(7):877-884. doi: 10.1038/onc.2016.253. Epub 2016 Aug 22. Review.

PMID:
27546617

Supplemental Content

Loading ...
Support Center